NCT06525220: An ongoing trial by Merus N.V.
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06525220 |
|---|---|
| Title | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 25, 2024 |
| Completion date | Jan. 31, 2028 |
| Required reporting date | Jan. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |